This means that passive immunization with tau antibodies is often a practical therapeutic focus on and the CSF degree of p-tau262/356 or in the microtubule binding area (MTBD) can function a valuable biomarker of tau pathology to watch tau therapeutics in medical trials. The aspects that figure o